Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management

Ethan A. Burns, Cesar Gentille, Barry H. Trachtenberg, Sai Ravi Pingali, Kartik Anand

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations

Abstract

Chimeric antigen receptor T-cells (CAR-T) are improving outcomes in pediatric and adult patients with relapsed or refractory B-cell acute lymphoblastic leukemias and subtypes of non-Hodgkin Lymphoma. As this treatment is being increasingly utilized, a better understanding of the unique toxicities associated with this therapy is warranted. While there is growing knowledge on the diagnosis and treatment of cytokine release syndrome (CRS), relatively little is known about the associated cardiac events that occur with CRS that may result in prolonged length of hospital stay, admission to the intensive care unit for pressor support, or cardiac death. This review focuses on the various manifestations of cardiotoxicity, potential risk factors, real world and clinical trial data on prevalence of reported cardiotoxicity events, and treatment recommendations.

Original languageEnglish (US)
Article number20
JournalDiseases
Volume9
Issue number1
DOIs
StatePublished - Mar 2021

Keywords

  • CAR-T
  • cardiotoxicity
  • cytokine release syndrome
  • heart failure
  • hypotension
  • leukemia
  • lymphoma

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management'. Together they form a unique fingerprint.

Cite this